血清COMP、ADAMTS-7对骨关节炎患者心血管疾病患病风险的预测价值  

Value of serum COMP and ADAMTS-7 in the risk assessment of cardiovascular disease in patients with osteoarthritis

作　　者：吕莉 侯新凤[1] 李楠 王慧杰 Li LYU;Xin-Feng HOU;Nan LI;Hui-Jie WANG(The Second Department of Cardiology,Luohe Central Hospital(The First Affiliated Hospital of Luohe Medical College),Luohe 462005,Henan Province,China)

机构地区：[1]漯河市中心医院(漯河市医专第一附属医院)心内二科,河南漯河462005

出　　处：《数理医药学杂志》2023年第2期127-133,共7页Journal of Mathematical Medicine

基　　金：河南省医学科技攻关计划(联合共建)项目(202102310813)。

摘　　要：目的 探讨血清软骨寡聚基质蛋白(cartilage oligomeric matrix protein,COMP)、血小板反应蛋白解整合素金属肽酶7(a disintegrin and metalloproteinase with thrombospondin motifs-7,ADAMTS-7)在骨关节炎(osteoarthritis,OA)患者并发心血管疾病(cerebrovascular disease,CVD)风险预测中的价值。方法 纳入120例OA患者设为OA组,另选择120例健康者设为健康组,检测两组COMP、ADAMTS-7水平,对比两组COMP、ADAMTS-7值。将OA组患者分为合并CVD组和未合并CVD组,再将未合并CVD组分为CVD低危组、中危组、高危组,比较各组血清COMP、ADAMTS-7。以合并CVD组患者为对象,分析血清COMP、ADAMTS-7与CVD病理特征的关系。结果 OA组患者血清COMP(14.35±2.13 vs. 7.13±1.02,P <0.001)、ADAMTS-7(56.54±5.23 vs. 30.13±3.15,P <0.001)均高于健康组;合并CVD组患者血清COMP(18.45±2.33 vs. 12.53±2.05,P=0.002)、ADAMTS-7(83.25±7.34 vs.45.15±5.23,P <0.001)均高于未合并CVD组;CVD高危组血清COMP、ADAMTS-7与中低危组存在显著差异;在合并CVD组患者中,动脉粥样硬化重度组血清COMP(P=0.007)、ADAMTS-7(P=0.009)高于轻中度组,心功能III-IV级组血清COMP(P=0.011)、ADAMTS-7(P=0.008)高于I-II级组,预后不良组患者血清COMP、ADAMTS-7均高于预后良好组(P <0.001)。结论 通过OA患者的血清COMP、ADAMTS-7值,可为预测OA患者并发CVD的风险提供相关参考,同时也可作为其病情及预后判断的重要参考指标。Objective To explore the application value of serum cartilage oligomeric matrix protein(COMP) and a disintegrin and metalloproteinase with thrombospondin motifs-7(ADAMTS-7) detection in the prediction of cardiovascular disease(CVD) risk in patients with osteoarthritis(OA). Method A total of 120 patients with OA were enrolled as OA group, and 120 healthy patients were selected as healthy group. The levels of COMP and ADAMTS-7 in the two groups were detected, and the index values of COMP and ADAMTS-7 were compared between the two groups. The patients in the OA group were divided into CVD group and nonCVD group, and the non-CVD group was divided into CVD low-risk group, intermediate-risk group and high-risk group, and the serum COMP and ADAMTS-7 of patients in each group were compared. The relationship between serum COMP, ADAMTS-7 and CVD pathological characteristics was analyzed in CVD group. Result The serum COMP(14.35±2.13 vs.7.13±1.02, P<0.001) and ADAMTS-7(56.54±5.23 vs. 30.13±3.15, P<0.001) were higher in the OA group than those in the healthy group, while the serum COMP(18.45±2.33 vs. 12.53±2.05,P=0.002) and ADAMTS-7(83.25±7.34 vs. 45.15 ±5.23, P<0.001) in the CVD group were higher than those in the non-CVD group, and there were significant differences between serum COMP and ADAMTS-7 in the high-risk group of CVD and the low-and medium-risk group.In the CVD group, serum COMP(P=0.007) and ADAMTS-7(P=0.009) were higher in the atherosclerotic severe group than in the mild to moderate group. The serum COMP(P=0.011)and ADAMTS-7(P=0.008) in the cardiac function grade III-IV group were higher than those in the grade I-II group. The serum COMP(P<0.001) and ADAMTS-7(P<0.001) were higher in the poor prognosis group than in the good prognosis group. Conclusion The detection of serum COMP and ADAMTS-7 in OA patients can provide information basis for predicting the risk degree of patients with CVD, and can also be used as an important reference index for the diagnosis and prognosis of patients with CVD.

关 键 词：骨关节炎 心血管疾病 COMP ADAMTS-7 风险预测 

分 类 号：R684.3[医药卫生—骨科学]